How Misguided Theories Delayed Alzheimer’s Cure

by Blog

The Impact of Faulty Hypotheses on Alzheimer’s Treatment Progress

The persistence of the Diet-Heart and Amyloid Hypotheses has profoundly shaped dietary guidelines and Alzheimer’s research, contributing to widespread insulin resistance and misdirected medical efforts. Despite the mounting evidence against these hypotheses, they have been sustained by powerful political and economic interests, delaying the discovery of more effective treatments. A shift towards understanding Alzheimer’s as a metabolic disease and revising public health policies is urgently needed to advance both prevention and treatment efforts.

(Note: About Us, a reference bibliography, related books and videos are all found at the end of this article.)

Embracing Mortality: The Strange Gift of Caregiving

by Blog

For many of us, death has often been a distant and abstract concept—something that happens to other people, at other times, in other places. Our modern world, with its focus on youth and vitality, often pushes the reality of death to the margins of our consciousness. However, when we step into the role of caregivers for seniors and the terminally ill, we can no longer afford the luxury of denial. The presence of death becomes a daily reality, forcing us to confront our own mortality and that of those around us.

This confrontation with mortality offers us a choice: we can succumb to morbidity and depression, or we can choose a path of acceptance and growth. We can make friends with death.

(Note: About Us, a reference bibliography, related books and videos are all found at the end of this article.)

Early Alzheimer’s Detection and Emerging Treatments

by Blog

The world is witnessing a growing crisis related to dementia. According to the Global Burden of Diseases, Injuries, and Risk Factors Study in 2019, an estimated 57.4 million people worldwide had dementia. By 2050, this number is expected to escalate to over 150 million, most of whom will have Alzheimer’s disease. With annual costs estimated at $1.3 trillion, the strain on care systems and families is significant.

Until recently, available treatments could only alleviate symptoms of dementia without halting the disease’s progress. This is now changing with new monoclonal antibody treatments such as Lecanemab, Aducanumab, and Donanemab. Experts have hailed these as the first disease-modifying treatments capable of clearing the amyloid plaques in the brain, which are responsible for most Alzheimer’s symptoms. However, the effectiveness of these treatments depends on early administration. Current diagnostic methods, primarily based on documenting mental decline, often fail to diagnose Alzheimer’s until significant brain damage has occurred. Thus, early diagnosis becomes vital for treatment efficiency.

(Note: About Us, a reference bibliography, related books and videos are all found at the end of this article.)